Aclar­is' mixed PhI­Ib eczema da­ta; Am­gen li­cens­es Xeris' tech; Bold­en Tx se­cures fund­ing

Aclaris Ther­a­peu­tics re­port­ed mixed re­sults for its JAK in­hibitor in a Phase IIb eczema study. The biotech seeks a part­ner for next steps. Aclaris an­nounced Wednes­day that at four weeks, its JAK 1/3 in­hibitor ATI-1777 sig­nif­i­cant­ly re­duced scores from base­line on a mea­sure of eczema sever­i­ty com­pared to place­bo in pa­tients who re­ceived the treat­ment twice dai­ly. How­ev­er, in those who re­ceived the treat­ment once a day, ATI-1777 failed to hit sta­tis­ti­cal sig­nif­i­cance. Aclaris’ shares $ACRS dropped about 25% Wednes­day morn­ing to be­low $1. Aclaris’ share val­ue has fall­en near­ly 95% over the past year af­ter a se­ries of clin­i­cal tri­al fails, and in De­cem­ber, the biotech laid off just un­der half of its staff. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER